NASDAQ:DBVT DBV Technologies Q3 2024 Earnings Report $19.65 0.00 (0.00%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$19.26 -0.39 (-1.98%) As of 05:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast DBV Technologies EPS ResultsActual EPS-$0.80Consensus EPS -$1.90Beat/MissBeat by +$1.10One Year Ago EPSN/ADBV Technologies Revenue ResultsActual Revenue$1.07 millionExpected Revenue$1.17 millionBeat/MissMissed by -$100.00 thousandYoY Revenue GrowthN/ADBV Technologies Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time2:00AM ETUpcoming EarningsDBV Technologies' Q2 2026 earnings is estimated for Wednesday, July 29, 2026, based on past reporting schedules, with a conference call scheduled at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release DBV Technologies Earnings HeadlinesDBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of "Moderate Buy" from Analysts1 hour ago | americanbankingnews.comCombined General Meeting of June 3, 2026May 13, 2026 | globenewswire.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker. | Behind the Markets (Ad)DBV Technologies (NASDAQ:DBVT) Stock Crosses Above 50-Day Moving Average - Time to Sell?May 13, 2026 | americanbankingnews.comDBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NasdaqMay 12, 2026 | globenewswire.comDBV Technologies Reports First Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comSee More DBV Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email. Email Address About DBV TechnologiesDBV Technologies (NASDAQ:DBVT) SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies. The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents. Viaskin Peanut is being evaluated in global clinical trials to assess its ability to reduce allergic reactions and improve patients’ threshold of reactivity to peanut exposure. DBV is also exploring the applicability of its technologies to other food allergens, including cow’s milk and egg, as part of its long-term pipeline strategy. Founded in 2002 and headquartered in Montrouge, France, DBV Technologies maintains research and development operations in Cambridge, Massachusetts, reflecting its transatlantic focus. The company has established alliances with academic institutions and leading allergy research centers to advance its clinical programs and expand its scientific expertise. Its development activities span North America, Europe and other regions where food allergy represents a significant public health challenge. Under the leadership of President and Chief Executive Officer Daniel Tasse, DBV Technologies has navigated multiple phases of clinical development and regulatory interactions. The company continues to engage with health authorities to define approval pathways and to establish its proprietary immunotherapy platform as a new standard of care for allergic diseases. View DBV Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingRobinhood, SoFi, and Webull Are Telling Very Different StoriesViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying Opportunity Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
